Westlake Closes $16 Million A Round for Stem Cell Cellular Therapies

Westlake Therapeutics of Hangzhou closed a $16 million Series A funding to develop red blood cell-based cellular medicines. The company develops its candidates by extracting hematopoietic stem cells, transforming them into medicine-carriers, and then transfusing them back into human bodies. The A round was led by CD Capital and included Sequoia Capital China. One year ago, Westlake raised $16 million in a Pre-A round from the Westlake Fund and Tasly Pharma, which remains a key investor. More details.... Stock Symbol: (SHA: 600535) Share this with colleagues: // //